Erste Asset Management GmbH Buys Shares of 23,800 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Erste Asset Management GmbH purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 23,800 shares of the company’s stock, valued at approximately $2,738,000.

Other institutional investors have also made changes to their positions in the company. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences in the second quarter valued at about $28,000. Innealta Capital LLC acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $30,000. EdgeRock Capital LLC bought a new position in Neurocrine Biosciences during the 2nd quarter worth approximately $35,000. Blue Trust Inc. boosted its stake in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after acquiring an additional 220 shares during the last quarter. Finally, Plato Investment Management Ltd grew its holdings in Neurocrine Biosciences by 44.1% during the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock valued at $59,000 after purchasing an additional 130 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $125.89 on Tuesday. The stock has a market capitalization of $12.75 billion, a PE ratio of 33.75 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98. The stock has a 50 day moving average price of $119.42 and a 200 day moving average price of $131.37.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. BMO Capital Markets reduced their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. JPMorgan Chase & Co. lifted their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Finally, StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. Five analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.